{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:17:12Z","timestamp":1778721432277,"version":"3.51.4"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>China's National Free Antiretroviral Treatment Program (NFATP) has significantly scaled up and standardized treatment since 2008. Meanwhile, no study worldwide has examined on a large scale the effects of rapid ART programme scale-up on treatment outcomes in resource-limited settings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used China's national HIV drug resistance (HIVDR) surveillance database to determine virological failure, acquired drug resistance and poor adherence rates after 12\u201315 months of first-line ART. A total of 2252 patients were examined, with 1431 patients having initiated ART before 2008 and 821 since 2008.<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>Since 2008, virological failure at 12\u201315 months of treatment improved from 26.6% to 12.1%, and HIVDR rates also significantly decreased from 15.4% to 5.4%. However, these successes are strongly associated with the standardized use of lamivudine-based regimens in place of didanosine-based regimens. Patients who initiated lamivudine-based regimens before 2008 showed significant improvement in adherence [missed doses adjusted OR (AOR), 0.65; 95% CI, 0.45\u20130.96], virological failure (AOR, 0.29; 95% CI, 0.22\u20130.39) and HIVDR outcomes (AOR, 0.29; 95% CI, 0.20\u20130.42) compared with those who initiated didanosine-based regimens. Meanwhile, among only patients on lamivudine-based regimens, no significant changes were observed between those who initiated before 2008 and those who initiated since 2008.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>China's NFATP has been largely successful throughout the scale-up, with an overall reduction in virological failure and HIVDR. However, excluding the effect of lamivudine-based regimens, it remains crucial for the programme to improve patient adherence and quality of care, particularly in key vulnerable populations such as those infected through injecting drug or blood routes.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkv078","type":"journal-article","created":{"date-parts":[[2015,4,8]],"date-time":"2015-04-08T21:03:22Z","timestamp":1428527002000},"page":"2097-2103","source":"Crossref","is-referenced-by-count":24,"title":["Reductions in virological failure and drug resistance in Chinese antiretroviral-treated patients due to lamivudine-based regimens, 2003\u201312"],"prefix":"10.1093","volume":"70","author":[{"given":"Hui","family":"Xing","sequence":"first","affiliation":[{"name":"State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS\/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhua","family":"Ruan","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS\/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny H.","family":"Hsi","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS\/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Kan","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS\/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingjie","family":"Liao","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS\/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuebing","family":"Leng","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS\/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS\/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cui","family":"He","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS\/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiming","family":"Shao","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS\/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the National HIVDR Working Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,4,7]]},"reference":[{"key":"2022020121025612300_DKV078C1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/QAD.0b013e32802ef30c","article-title":"Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy","volume":"21","author":"Lima","year":"2007","journal-title":"AIDS"},{"key":"2022020121025612300_DKV078C2","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(06)69861-9","article-title":"A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial","volume":"368","author":"MacArthur","year":"2006","journal-title":"Lancet"},{"key":"2022020121025612300_DKV078C3","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators","volume":"338","author":"Palella","year":"1998","journal-title":"New Engl J Med"},{"key":"2022020121025612300_DKV078C4","first-page":"659","article-title":"Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens","volume":"160","author":"Hogg","year":"1999","journal-title":"CMAJ"},{"key":"2022020121025612300_DKV078C5","doi-asserted-by":"crossref","first-page":"18797","DOI":"10.7448\/IAS.17.1.18797","article-title":"Disease patterns and causes of death of hospitalized HIV-positive adults in West Africa: a multicountry survey in the antiretroviral treatment era","volume":"17","author":"Lewden","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"2022020121025612300_DKV078C6","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/QAD.0000000000000243","article-title":"Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy: UK cohort study","volume":"28","author":"May","year":"2014","journal-title":"AIDS"},{"key":"2022020121025612300_DKV078C7","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/cid\/cit794","article-title":"Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: implications for improving outcomes","volume":"58","author":"Jarvis","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2022020121025612300_DKV078C8","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/QAI.0b013e31829ceb14","article-title":"Reduction in early mortality on antiretroviral therapy for adults in rural South Africa since change in CD4+ cell count eligibility criteria","volume":"65","author":"Lessells","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022020121025612300_DKV078C9","author":"WHO"},{"key":"2022020121025612300_DKV078C10","author":"WHO"},{"key":"2022020121025612300_DKV078C11","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1473-3099(11)70097-4","article-title":"Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study","volume":"11","author":"Zhang","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"2022020121025612300_DKV078C12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-151-4-200908180-00006","article-title":"Five-year outcomes of the China National Free Antiretroviral Treatment Program","volume":"151","author":"Zhang","year":"2009","journal-title":"Ann Intern Med"},{"key":"2022020121025612300_DKV078C13","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/ije\/dyp233","article-title":"Cohort profile: the Chinese national free antiretroviral treatment cohort","volume":"39","author":"Ma","year":"2010","journal-title":"Int J Epidemiol"},{"key":"2022020121025612300_DKV078C14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1086\/649215","article-title":"Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China","volume":"50","author":"Ma","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2022020121025612300_DKV078C15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/590945","article-title":"The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China","volume":"47","author":"Zhang","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2022020121025612300_DKV078C16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/QAI.0b013e31824c3d9f","article-title":"Association between missed early visits and mortality among patients of china national free antiretroviral treatment cohort","volume":"60","author":"Zhang","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022020121025612300_DKV078C17","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1097\/01.aids.0000233577.33973.fa","article-title":"Co-infection with HIV and hepatitis C virus in former plasma\/blood donors: challenge for patient care in rural China","volume":"20","author":"Qian","year":"2006","journal-title":"AIDS"},{"key":"2022020121025612300_DKV078C18","first-page":"3514","article-title":"Expansion of China's free antiretroviral treatment program","volume":"125","author":"Zhao","year":"2012","journal-title":"Chin Med J (Engl)"},{"key":"2022020121025612300_DKV078C19","volume-title":"China Free ART Manual","author":"Zhang","year":"2005","edition":"1st edn"},{"key":"2022020121025612300_DKV078C20","volume-title":"China Free ART Manual","author":"Zhang","year":"2008","edition":"3nd edn"},{"key":"2022020121025612300_DKV078C21","volume-title":"Chinese Center for Disease Control and Prevention"},{"key":"2022020121025612300_DKV078C22","volume-title":"World Health Organization Global Strategy for the Surveillance and Monitoring of HIV Drug Resistance 2012","author":"WHO"},{"key":"2022020121025612300_DKV078C23","doi-asserted-by":"crossref","first-page":"e54917","DOI":"10.1371\/journal.pone.0054917","article-title":"HIV drug resistance and its impact on antiretroviral therapy in Chinese HIV-infected patients","volume":"8","author":"Xing","year":"2013","journal-title":"PLoS One"},{"key":"2022020121025612300_DKV078C24","doi-asserted-by":"crossref","first-page":"e62408","DOI":"10.1371\/journal.pone.0062408","article-title":"Incidence and associated factors of HIV drug resistance in Chinese HIV-infected patients receiving antiretroviral treatment","volume":"8","author":"Xing","year":"2013","journal-title":"PLoS One"},{"key":"2022020121025612300_DKV078C25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/157016211795569122","article-title":"Factors associated with HIV virologic failure among patients on HAART for one year at three sentinel surveillance sites in China","volume":"9","author":"Wang","year":"2011","journal-title":"Curr HIV Res"},{"key":"2022020121025612300_DKV078C26","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1365-3156.2010.02621.x","article-title":"Virologic outcomes of first-line HAART and associated factors among Chinese patients with HIV in three sentinel antiretroviral treatment sites","volume":"15","author":"Ruan","year":"2010","journal-title":"Trop Med Int Health"},{"key":"2022020121025612300_DKV078C27","doi-asserted-by":"crossref","first-page":"e88305","DOI":"10.1371\/journal.pone.0088305","article-title":"Virological outcomes and drug resistance in Chinese patients after 12 months of lamivudine-based first-line antiretroviral treatment, 2011\u20132012","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"2022020121025612300_DKV078C28","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1089\/aid.2006.0196","article-title":"Genetic diversity and drug resistance of human immunodeficiency virus type 1 (HIV-1) strains circulating in Shanghai","volume":"23","author":"Zhong","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"Suppl 1","key":"2022020121025612300_DKV078C29","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/QAI.0b013e3181c7d363","article-title":"The prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in China","volume":"53","author":"Liao","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022020121025612300_DKV078C30","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"2022020121025612300_DKV078C31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/135965350801302S07","article-title":"World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites","volume":"13","author":"Jordan","year":"2008","journal-title":"Antivir Ther"},{"key":"2022020121025612300_DKV078C32","first-page":"377","article-title":"Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review","volume":"91","author":"McMahon","year":"2013","journal-title":"Bull WHO"},{"key":"2022020121025612300_DKV078C33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/QAI.0b013e31819ff102","article-title":"Response to ZDV\/ddI containing combination antiretroviral therapy among HIV-1 subtype C infected adults in Botswana: two-year outcomes from a randomized clinical trial","volume":"51","author":"Bussmann","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022020121025612300_DKV078C34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/OLQ.0b013e31827fd4d4","article-title":"Evaluation of harm reduction programs on seroincidence of HIV, hepatitis B and C,and syphilis among intravenous drug users in southwest China","volume":"40","author":"Ruan","year":"2013","journal-title":"Sex Transm Dis"},{"issue":"Suppl 4","key":"2022020121025612300_DKV078C35","doi-asserted-by":"crossref","first-page":"S320","DOI":"10.1093\/cid\/cir1016","article-title":"Surveys of transmitted HIV drug resistance in 7 geographic Regions in China, 2008\u20132009","volume":"54","author":"Liao","year":"2012","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/70\/7\/2097\/42355132\/jac_70_7_2097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/70\/7\/2097\/42355132\/jac_70_7_2097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T14:19:49Z","timestamp":1651673989000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/70\/7\/2097\/777270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,7]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,4,7]]},"published-print":{"date-parts":[[2015,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkv078","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,7]]},"published":{"date-parts":[[2015,4,7]]}}}